Nathalie D. Mckenzie, MD

Nathalie D. Mckenzie, MD

Gynecologic Oncologist

Cancer

Nathalie Mckenzie

Overview

Natalie Dauphin McKenzie, MD, MSPH, is a board-certified gynecologic oncologist with a breadth of experience providing advanced treatments including minimally invasive and robotic-assisted procedures for women with all types of gynecologic cancer. She earned her medical degree with research honors at the University of New York at Buffalo and undertook her residency training and fellowship at the University of Miami/Jackson Memorial Hospital. She also earned her Master of Science in Public Health with honors while completing her fellowship training.

Dr. McKenzie is an award-winning physician who is known for her expertise in radical debulking procedures for removing advanced tumors. She is particularly interested in HPV-related neoplasia and patient-driven cancer treatment. She is also a multilingual provider with fluency in English, French, medical Spanish and Haitian Creole.

Articles

Fused Clitoral Hood Presenting as a Periclitoral Mass

OBSTETRICS AND GYNECOLOGY

2022

CERVICAL CANCER TREATED BY NEOADJUVANT CHEMOTHERAPY FOLLOWED BY RADICAL SURGERY: A CASE SERIES FROM MIREBALAIS, HAITI

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

2022

MALIGNANT PERITONEAL CYTOLOGIC CONTAMINATION WITH ROBOTIC HYSTERECTOMY FOR ENDOMETRIAL CANCER

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

2022

Exploring Bias in Scientific Peer Review: An ASCO Initiative

JCO ONCOLOGY PRACTICE

2022

Impact of Lifestyle Interventions on Gynecologic Cancers: Beyond Diet and Exercise

AMERICAN JOURNAL OF LIFESTYLE MEDICINE

2022

Single-Institution Retrospective Analysis of Ovarian Cancer Outcomes from the Middle Eastern Republic of Georgia

INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY

2022

Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives

ONCOTARGETS AND THERAPY

2022

The gut microbiome and cancer immunotherapeutics: A review of emerging data and implications for future gynecologic cancer research

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

2021

Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives

GYNECOLOGIC ONCOLOGY

2021

Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer

CANCER

2021

More Publication Information

Education & Training

Education

University of New York at Buffalo School of Medicine, Buffalo, NY

Residency

Memorial Sloan Kettering Cancer Center, NY

Fellowship

University of Miami/ Jackson Memorial Hospital, Miami, FL

Specialty

Gynecology Oncology

Board Certifications

American Board of Obstetrics and Gynecology

Associated Clinical Trials

NCT05256225

NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA

Icon for trial | NRG GY026 NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL S

This study is currently enrolling.

This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer quest ...